Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

Stanway, Susannah J and Purohit, Atul and Woo, L W Lawrence and Sufi, Saulat and Vigushin, David and Ward, Rebecca and Wilson, Richard H and Stanczyk, Frank Z and Dobbs, Nicola and Kulinskaya, Elena and Elliott, Moira and Potter, Barry V L and Reed, Michael J and Coombes, R Charles (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clinical Cancer Research, 12 (5). pp. 1585-92. ISSN 1078-0432

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

Inhibition of steroid sulfatase (STS), the enzyme responsible for the hydrolysis of steroid sulfates, represents a potential novel treatment for postmenopausal women with hormone-dependent breast cancer. Estrone and DHEA are formed by this sulfatase pathway and can be converted to steroids (estradiol and androstenediol, respectively), which have potent estrogenic properties.